The aim of the study was to determine the activity and toxicity of melphalan as a single agent given in up-front therapy for patients with newly-diagnosed Ewing's family tumours with bone/bone marrow metastases. Nineteen patients were enrolled from 2001 to 2004. The treatment consisted of up-front therapy with melphalan (two courses of 50 mg/m2, 3 weeks apart). The overall rate of response to melphalan (complete response + partial response, according to the RECIST criteria) was 78%. Transient grade 3-4 neutropenia, thrombocytopenia and anaemia were recorded in 97%, 81% and 28% of melphalan courses, respectively. No other relevant toxicities were recorded. Melphalan proved to be active in up-front treatment at non-myeloablative doses, and its toxicity was predictable and manageable. The schedule adopted did not interfere with any further intensive chemotherapy or myeloablative treatment in the majority of cases.
Response to melphalan in up-front investigational window therapy for patients with metastatic Ewing's family tumours / R. Luksch, G. Grignani, F. Fagioli, A. Brach del Prever, M. Podda, S. Aliberti, M. Casanova, A. Prete, G. Hanau, A. Tamburini, P. Allione, A. Tienghi, S. Ferrari,P. Collini, A. Marchianò, L. Gandola, M. Aglietta, E. Madon, P. Picci, F. Fossati-Bellani. - In: EUROPEAN JOURNAL OF CANCER. - ISSN 0959-8049. - 43:5(2007 Mar 01), pp. 885-890. [10.1016/j.ejca.2006.09.027]
Response to melphalan in up-front investigational window therapy for patients with metastatic Ewing's family tumours
M. Podda;
2007
Abstract
The aim of the study was to determine the activity and toxicity of melphalan as a single agent given in up-front therapy for patients with newly-diagnosed Ewing's family tumours with bone/bone marrow metastases. Nineteen patients were enrolled from 2001 to 2004. The treatment consisted of up-front therapy with melphalan (two courses of 50 mg/m2, 3 weeks apart). The overall rate of response to melphalan (complete response + partial response, according to the RECIST criteria) was 78%. Transient grade 3-4 neutropenia, thrombocytopenia and anaemia were recorded in 97%, 81% and 28% of melphalan courses, respectively. No other relevant toxicities were recorded. Melphalan proved to be active in up-front treatment at non-myeloablative doses, and its toxicity was predictable and manageable. The schedule adopted did not interfere with any further intensive chemotherapy or myeloablative treatment in the majority of cases.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
